Identification

Name
Cefaclor
Accession Number
DB00833  (APRD00243)
Type
Small Molecule
Groups
Approved
Description

Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

Structure
Thumb
Synonyms
  • 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
  • CCL
  • Cefaclor
  • Cefaclor anhydrous
  • Cefacloro
  • Cefaclorum
  • Céfeaclor
  • Cephaclor
External IDs
Compound 99638 / S 6472
Product Ingredients
IngredientUNIICASInChI Key
Cefaclor monohydrate69K7K19H4L70356-03-5WKJGTOYAEQDNIA-IOOZKYRYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CeclorCapsule500 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorCapsule250 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorPowder, for suspension125 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorPowder, for suspension250 mgOralPendopharm Division Of De Pharmascience Inc1980-12-312016-10-25Canada
CeclorPowder, for suspension375 mgOralPendopharm Division Of De Pharmascience Inc1990-12-312016-10-25Canada
CefaclorSuspension250 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
CefaclorCapsule500 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
CefaclorSuspension375 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
CefaclorSuspension125 mgOralMm Therapeutics Inc1998-06-112009-12-18Canada
CefaclorCapsule250 mgOralMm Therapeutics Inc1998-06-042009-12-18Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cefaclorCapsule500 mgOralApotex Corporation1997-01-20Not applicableCanada
Apo-cefaclorPowder375 mgOralApotex Corporation1998-03-06Not applicableCanada
Apo-cefaclorPowder125 mgOralApotex Corporation1998-03-06Not applicableCanada
Apo-cefaclorCapsule250 mgOralApotex Corporation1997-01-20Not applicableCanada
Apo-cefaclorPowder250 mgOralApotex Corporation1998-03-06Not applicableCanada
CefaclorSuspension375 mg/5mLOralPack Pharmaceuticals LLC2012-10-31Not applicableUs
CefaclorCapsule250 mg/1OralAlvogen, Inc.2010-01-18Not applicableUs
CefaclorSuspension250 mg/5mLOralCarlsbad Technology, Inc.2012-03-27Not applicableUs
CefaclorTablet, film coated, extended release500 mg/1OralTeva2002-09-26Not applicableUs00093 1087 01 nlmimage10 9e29cf5e
CefaclorCapsule250 mg/1OralA S Medication Solutions2007-05-012017-06-20Us
International/Other Brands
Alenfral (Choseido Pharmaceutical) / Alfacet (Galenika) / Alfatil (Dexo) / Alfatil LP (Dexo) / Ceclor CD (Lilly) / Distaclor (Flynn) / Keflor (Alphapharm) / Kefral (Shionogi Seiyaku) / Panacef (Valeas) / Panoral (Eberth) / Raniclor (Ranbaxy Pharmaceuticals Inc.)
Categories
UNII
3Z6FS3IK0K
CAS number
53994-73-3
Weight
Average: 367.807
Monoisotopic: 367.039354348
Chemical Formula
C15H14ClN3O4S
InChI Key
QYIYFLOTGYLRGG-GPCCPHFNSA-N
InChI
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
IUPAC Name
(6R,7R)-7-[(2R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(Cl)=C(N1C(=O)[[email protected]]2NC(=O)[[email protected]](N)C1=CC=CC=C1)C(O)=O

Pharmacology

Indication

For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.

Structured Indications
Pharmacodynamics

Cefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ß-hemolytic streptococci). Gram-negative aerobes - Escherichia coli, Haemophilus influenzae (including ß-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.

Mechanism of action

Cefaclor, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that cefaclor interferes with an autolysin inhibitor.

TargetActionsOrganism
APenicillin-binding protein 3
inhibitor
Streptococcus pneumoniae
APenicillin-binding protein 1A
inhibitor
Clostridium perfringens (strain 13 / Type A)
Absorption

Well absorbed after oral administration, independent of food intake.

Volume of distribution
Not Available
Protein binding

23.5%

Metabolism

No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).

Route of elimination

Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.

Half life

0.6-0.9 hour

Clearance
Not Available
Toxicity

Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolCefaclor may increase the anticoagulant activities of Acenocoumarol.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cefaclor.Investigational
ClorindioneCefaclor may increase the anticoagulant activities of Clorindione.Experimental
DicoumarolCefaclor may increase the anticoagulant activities of Dicoumarol.Approved
DiphenadioneCefaclor may increase the anticoagulant activities of Diphenadione.Experimental
Ethyl biscoumacetateCefaclor may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindioneCefaclor may increase the anticoagulant activities of Fluindione.Investigational
PhenindioneCefaclor may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCefaclor may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor.Approved
ProbenecidThe serum concentration of Cefaclor can be increased when it is combined with Probenecid.Approved
TioclomarolCefaclor may increase the anticoagulant activities of Tioclomarol.Experimental
WarfarinCefaclor may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
  • Preferably on an empty stomach, not really problematic.

References

Synthesis Reference

Bing L. Wong, Yong-Qiang Shen, Yung-Pin Chen, "Enzymatic production of cefaclor from cephalexin." U.S. Patent US5939299, issued November, 1987.

US5939299
General References
  1. Hebert AA, Sigman ES, Levy ML: Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991 Nov;25(5 Pt 1):805-8. [PubMed:1802903]
  2. Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T: Serum sickness-like syndrome associated with cefaclor therapy. Allergy. 1992 Aug;47(4 Pt 2):439-40. [PubMed:1456417]
External Links
Human Metabolome Database
HMDB14971
KEGG Drug
D00256
KEGG Compound
C06877
PubChem Compound
51039
PubChem Substance
46507693
ChemSpider
46260
BindingDB
42131
ChEBI
3478
ChEMBL
CHEMBL680
Therapeutic Targets Database
DAP000442
PharmGKB
PA164749137
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefaclor
ATC Codes
J01DC04 — Cefaclor
AHFS Codes
  • 08:12.06.08 — Second Generation Cephalosporins
FDA label
Download (186 KB)
MSDS
Download (43.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1RecruitingTreatmentCorneal Ectasia / Keratoconus1
Not AvailableCompletedTreatmentSnoring / Strep Throat1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
  • Ceph international corp
  • Clonmel healthcare ltd
  • Hikma pharmaceuticals
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marsam pharmaceuticals llc
  • Ranbaxy pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Yung shin pharmaceutical industrial co ltd
  • Acs dobfar info sa
  • Ranbaxy laboratories ltd
  • World gen llc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
CapsuleOral500 mg/1
For suspensionOral125 mg/5mL
For suspensionOral250 mg/5mL
For suspensionOral375 mg/5mL
SuspensionOral125 mg
SuspensionOral125 mg/5mL
SuspensionOral187 mg/5mL
SuspensionOral250 mg
SuspensionOral250 mg/5mL
SuspensionOral375 mg
SuspensionOral375 mg/5mL
Tablet, film coated, extended releaseOral500 mg/1
Powder, for suspensionOral125 mg
Powder, for suspensionOral187 mg
Powder, for suspensionOral250 mg
Powder, for suspensionOral375 mg
PowderOral125 mg
PowderOral250 mg
PowderOral375 mg
SuspensionOral25 mg
SuspensionOral50 mg
SuspensionOral75 mg
CapsuleOral500 mg
CapsuleOral250 mg
Powder, for solutionOral25 mg
Powder, for solutionOral50 mg
Powder, for solutionOral75 mg
Prices
Unit descriptionCostUnit
Ceclor 15 500 mg capsule Bottle70.0USD bottle
Ceclor 375 mg/5ml Suspension 100ml Bottle59.99USD bottle
Ceclor 250 mg/5ml Suspension 150ml Bottle58.98USD bottle
Cefaclor 250 mg/5ml Suspension 150ml Bottle53.87USD bottle
Cefaclor 375 mg/5ml Suspension 100ml Bottle53.87USD bottle
Ceclor 15 250 mg capsule Bottle38.0USD bottle
Ceclor 125 mg/5ml Suspension 150ml Bottle34.99USD bottle
Ceclor 187 mg/5ml Suspension 100ml Bottle34.99USD bottle
Ceclor 250 mg/5ml Suspension 75ml Bottle31.99USD bottle
Cefaclor 125 mg/5ml Suspension 150ml Bottle29.41USD bottle
Cefaclor 250 mg/5ml Suspension 75ml Bottle29.37USD bottle
Cefaclor 187 mg/5ml Suspension 100ml Bottle29.26USD bottle
Cefaclor 375 mg/5ml Suspension 50ml Bottle27.44USD bottle
Cefaclor 187 mg/5ml Suspension 50ml Bottle14.92USD bottle
Cefaclor 125 mg/5ml Suspension 75ml Bottle14.7USD bottle
Ceclor 500 mg pulvule5.69USD each
Cefaclor 500 mg capsule4.05USD capsule
Cefaclor CR 500 mg 12 Hour tablet3.79USD tablet
Ceclor 250 mg pulvule3.28USD each
Raniclor 375 mg chewable tablet2.98USD tablet
Cefaclor 250 mg capsule2.07USD capsule
Raniclor 250 mg chewable tablet1.99USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)327 °CNot Available
water solubility1E+004 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.21 mg/mLALOGPS
logP0.85ALOGPS
logP-2.3ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.03ChemAxon
pKa (Strongest Basic)7.44ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area112.73 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity89.56 m3·mol-1ChemAxon
Polarizability35.11 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8839
Blood Brain Barrier-0.9817
Caco-2 permeable-0.8239
P-glycoprotein substrateSubstrate0.6569
P-glycoprotein inhibitor INon-inhibitor0.9413
P-glycoprotein inhibitor IINon-inhibitor0.9955
Renal organic cation transporterNon-inhibitor0.9369
CYP450 2C9 substrateNon-substrate0.8314
CYP450 2D6 substrateNon-substrate0.8361
CYP450 3A4 substrateNon-substrate0.5597
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9236
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9193
Ames testNon AMES toxic0.6676
CarcinogenicityNon-carcinogens0.8489
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.2960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9966
hERG inhibition (predictor II)Non-inhibitor0.85
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0590000000-34857060856b0cac1c04
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00p0-1950000000-9f8a92f4a857c98b63ab
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ukc-3920000000-86cb2f866ab059592333
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0fkl-4910000000-c6f6c93efa7b2b3bc3d2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0abc-7900000000-98306dadbeccb72e1ba8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0abc-9700000000-f4a33b4825c13beb1024
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-0900000000-ec391756df89ec0d9544
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-0900000000-f3ee64eb3dc5aa901340
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aor-0900000000-c4d5197048a0a6ec18a6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aor-1900000000-5f6c6fcc3196ef576a9d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066r-3900000000-5151a520059ba886f4cc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066u-6900000000-e164f9cd4b1781b2168d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dl-1911000000-144d67b80e602cc73566
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05fu-0910000000-50ca0c98776044283551

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids and derivatives
Alternative Parents
Cephems / Aralkylamines / 1,3-thiazines / Benzene and substituted derivatives / Vinylogous halides / Tertiary carboxylic acid amides / Amino acids / Azetidines / Vinyl chlorides / Thiohemiaminal derivatives
show 13 more
Substituents
N-acyl-alpha amino acid or derivatives / Cephem / Aralkylamine / Meta-thiazine / Monocyclic benzene moiety / Benzenoid / Beta-lactam / Tertiary carboxylic acid amide / Vinylogous halide / Azetidine
show 32 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin (CHEBI:3478)

Targets

Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not Available
Gene Name
pbp3
Uniprot ID
Q75Y35
Uniprot Name
Penicillin-binding protein 3
Molecular Weight
45209.84 Da
References
  1. Chambers HF, Miick C: Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar;36(3):656-61. [PubMed:1622180]
Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring glycosyl groups
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
pbpA
Uniprot ID
Q8XJ01
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
75176.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chambers HF, Miick C: Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrob Agents Chemother. 1992 Mar;36(3):656-61. [PubMed:1622180]
  4. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Zuccotti G, Dauria E, Torcoletti M, Lodi F, Bernardo L, Riva E: Clinical and pro-host effects of cefaclor in prophylaxis of recurrent otitis media in HIV-infected children. J Int Med Res. 2001 Jul-Aug;29(4):349-54. [PubMed:11675909]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50. [PubMed:10052994]
  2. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
  3. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
  2. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33